NCT02046213

An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the metabolism and excretion of \[14C\]E2006 in healthy male subjects.

Detailed description

This is an open-label, single-dose study in healthy male subjects. The study will have 2 phases: Pretreatment and Treatment. The Pretreatment Phase will last up to 21 days and will consist of a Screening Period and a Baseline Period, during which each subject's eligibility will be determined and assessments will be conducted.

Conditions

• Metabolism and Excretion

Interventions

Type	Name	Description
DRUG	E2006	Single oral 10mg dose of 100 uCi \[14C\]E2006

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-04-01
• Completion: 2014-05-01
• First posted: 2014-01-27
• Last updated: 2015-11-03

Locations

1 site across 1 country: United States